BOLALARNING ICHAK TUTULISHIDAGI MIKRORNK DARAJASINING IFODASI
##article.subject##:
Ichakning normal o'tkazuvchanligi (NK), Mikrornk-21, Mikrornk-122, Mikrornk regulyatsiyasi, Istiqbolli biomarkerlar, ROC tahlili##article.abstract##
MikroRNKlar, genlarni tartibga soluvchi funktsiyalarga ega bo'lgan kichik kodlanmaydigan RNK molekulalari sinfi, turli kasalliklarning patogenezida hal qiluvchi rol o'ynaydi. Hozirgi texnologik yutuqlar turli to'qimalarda mikroRNKlarning ko'pligini aniq va yuqori o'tkazuvchanlik bilan aniqlash imkonini beradi [1, 2]. Yaqinda hujayradan tashqari aylanma mikroRNKlar qon va najasga asoslangan kasalliklarning yuqori barqaror biomarkerlari sifatida namoyon bo'la boshladi [3, 5]. Aylanma mikroRNKlar va klinik fenotiplar o'rtasidagi o'zaro ta'sirlarni tushunish murakkab kasalliklar va belgilar haqidagi bilimlarimizni kengaytirishi mumkin. Boshqa tomondan, qonga asoslangan biomarkerlar va boshqa biomateriallardan (masalan, najasda) foydalanishning afzalliklarini hisobga olgan holda, aylanma mikroRNKlar biomarkerlar sifatida kasalliklarni tashxislash va davolashni yaxshilashi mumkin. Ayniqsa, biz aylanma mikroRNKlarni bolalarda ichak tutilishining biomarkerlari sifatida aniqlashdagi yutuqlarni ko'rib chiqdik. Tadqiqot ma'lumotlari ichak tutilishini davolash uchun aylanma mikroRNKlardan foydalanishning istiqbolli kelajagini ko'rsatdi. MikroRNKlar (MikroRNKlar) gen ekspressiyasini transkripsiyadan keyin tartibga soluvchi kichik kodlanmagan RNKlardir [6]. MikroRNK ifodasidagi o'zgarishlar to'qima namunalarida ham, najas kabi oson kirish mumkin bo'lgan namunalarda ham bir qator ichak kasalliklarida qayd etilgan. Patogen infektsiyalar, parhez, toksinlar va boshqa atrof-muhit omillari mikrornk ifodasiga ta'sir qiladi deb o'ylashadi [5, 7]. Biroq, odamlarda mikroRNKdagi o'zgarishlar hali to'liq o'rganilmagan.
Библиографические ссылки
Al-Sadi, R., Engers, J., and Abdulqadir, R. (2020). Talk about Micromanaging! Role of microRNAs in Intestinal Barrier Function. Am. J. Physiol.-Gastrointest. Liver Physiol. 319 (2), G170–G174. doi:10.1152/ajpgi.00214.2020
Amour, C., Gratz, J., Mduma, E., Svensen, E., Rogawski, E. T., McGrath, M., et al. (2016). Epidemiology and Impact of Campylobacter Infection in Children in 8 Low-Resource Settings: Results from the MAL-ED Study. Clin. Infect. Dis. 63 (9), ciw542–1179. doi:10.1093/cid/ciw542.
Bi, Y., Liu, G., and Yang, R. (2009). MicroRNAs: Novel Regulators during the Immune Response. J. Cel. Physiol. 218 (3), 467–472. doi:10.1002/ jcp.21639.
Bischoff, S. C., Barbara, G., Buurman, W., Ockhuizen, T., Schulzke, J.-D., Serino, M., et al. (2014). Intestinal Permeability - a New Target for Disease Prevention and Therapy. BMC Gastroenterol. 14 (1), 1–25. doi:10.1186/s12876-014-0189-7 .
Bjarnason, I. (2017). The Use of Fecal Calprotectin in Inflammatory Bowel Disease. Gastroenterol. Hepatol. 13 (1), 53.
Bray, A. E., Ahmed, S., Das, S. K., Khan, S. H., Chisti, M. J., Ahmed, T., et al. (2019). Viral Pathogen-Specific Clinical and Demographic Characteristics of Children with Moderate-To- Severe Diarrhea in Rural Bangladesh. Am. J. Trop. Med. Hyg. 101 (2), 304–309. doi:10.4269/ajtmh.19-0152.
Bruewer, M., Luegering, A., Kucharzik, T., Parkos, C. A., Madara, J. L., Hopkins, A. M., et al. (2003). Proinflammatory Cytokines Disrupt Epithelial Barrier Function by Apoptosis- independent Mechanisms. J. Immunol. 171 (11), 6164–6172. doi:10.4049/jimmunol.171.11.6164.
